Lisata Therapeutics, Inc. develops investigational therapies for advanced solid tumors and other serious diseases. Its principal product candidate, certepetide, is a proprietary iRGD cyclic peptide designed to activate an uptake pathway that can improve tumor targeting and penetration by co-administered or tethered anti-cancer agents.
Recurring Lisata news covers clinical and preclinical data involving certepetide, collaborations and license agreements tied to antibody-drug conjugates and other delivery technologies, development-rights changes for regional markets, financial results, business updates, and corporate matters affecting governance or capital structure.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, a clinical-stage pharmaceutical company, announced that CEO David J. Mazzo, PhD, will present at three upcoming conferences:
- LSX World Congress: May 3-4, 2023 in London. Dr. Mazzo's presentation will be on May 3 at 11:15 a.m. British Summer Time.
- Sidoti Micro-Cap Conference: May 10-11, 2023, virtual. Dr. Mazzo will present on May 10 at 10:00 a.m. Eastern Time.
- Bio€quity Europe 2023: May 14-16, 2023 in Dublin. Dr. Mazzo's presentation is set for May 15 at 1:41 p.m. Irish Standard Time.
Lisata develops innovative therapies for advanced solid tumors and is advancing its lead candidate, LSTA1, designed to enhance anti-cancer drug delivery while minimizing effects on normal tissues. The company is actively exploring treatment modalities for various solid tumors.